Gyno-Daktarin Vaginale (Miconazole Nitrate)

Gyno-Daktarin Vaginale is indicated for the treatment of vulvovaginal candidiasis, a common yeast infection of the female genital tract.

• Treatment of acute vulvovaginal candidiasis caused by Candida species.
• Management of recurrent vulvovaginal yeast infections when prescribed by a healthcare professional.
• Relief of associated symptoms such as itching, burning, and abnormal discharge.
• Use as part of a comprehensive antifungal regimen for confirmed fungal infections of the vagina.
• Adjunctive therapy in patients with mixed bacterial‑fungal vaginal infections, following medical assessment.
• Application in post‑antibiotic vaginal dysbiosis where yeast overgrowth is documented.

Possible adverse reactions associated with vaginal use of Gyno-Daktarin Vaginale are generally mild, but some users may experience more serious effects.

Common

• Local irritation or burning at the application site.
• Vaginal itching or mild discomfort.
• Unusual vaginal discharge or spotting.
• Headache.
• Mild abdominal cramps.
• Temporary increase in vaginal discharge.
• Mild burning sensation during urination.
• Transient feeling of pressure in the pelvic area.

Serious

• Severe allergic reaction such as rash, swelling, or difficulty breathing.
• Persistent or worsening vaginal symptoms despite treatment.
• Signs of secondary infection, such as fever or foul odor.
• Liver enzyme abnormalities.
• Severe dizziness or fainting.
• Signs of systemic infection such as chills or rapid heartbeat.

When using Gyno-Daktarin Vaginale, certain precautions should be observed to ensure safe and effective treatment.

• Confirm diagnosis of vulvovaginal candidiasis before initiating therapy.
• Avoid using the product if you have a known hypersensitivity to miconazole or other imidazole antifungals.
• Do not insert the applicator deeper than recommended; follow the product instructions for proper placement.
• Inform your healthcare provider of any existing medical conditions, especially liver disease or immunosuppression.
• Discuss use with a physician during pregnancy or breastfeeding, as safety information may be limited.
• Keep the medication out of reach of children and store it according to label directions.

Potential drug interactions with vaginal miconazole nitrate are limited, but certain substances may affect its efficacy or increase the risk of adverse effects.

Avoid

• Concurrent systemic azole antifungals (e.g., fluconazole) that may increase systemic exposure.
• Use with topical products containing other antifungal agents unless directed by a clinician.
• Avoid using intravaginal douches or soaps immediately before or after application.

Use with caution

• Hormonal contraceptives, as miconazole may theoretically affect hormone metabolism.
• Anticoagulants such as warfarin, though systemic absorption from vaginal use is low, monitoring is advised.
• Other vaginal medications (e.g., spermicides) that could alter local absorption.
• Patients on systemic antifungal therapy should inform their physician to evaluate potential cumulative exposure.